Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy
Sanofi has announced the discontinuation of its Phase 3 MOBILIZE study evaluating…
FDA approves Lilly’s EBGLYSS® for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis
The U.S. FDA has approved a new maintenance dosing regimen for Eli…
Rigel Pharmaceuticals Signs Global Licensing Deal for VEPPANU™ Breast Cancer Treatment
Rigel Pharmaceuticals has entered an exclusive global licensing agreement with Arvinas and…
GE HealthCare Doses First Patient in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent
GE HealthCare has dosed the first patient in its Phase 2/3 LUMINA…
Phase 3 EMBARK Study Confirms XTANDI Plus Leuprolide Improves Overall Survival in Non-Metastatic Prostate Cancer
Pfizer Inc. and Astellas Pharma Inc. announced positive topline results from the…
